Managing Chronic Immune Thrombocytopenia: Opportunities for Oncology Pharmacists to Optimize Patient Care

Managing Chronic Immune Thrombocytopenia: Opportunities for Oncology Pharmacists to Optimize Patient Care

Faculty

Julianne O. Darling, PharmD, BCOP
Clinical Pharmacy Specialist, Outpatient Oncology
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana
 
Program Description

Immune thrombocytopenia (ITP) is a condition in which the immune system destroys platelets. ITP has an incidence of 2 to 5 per 100,000 and can be an isolated primary condition, or it may be secondary to other conditions. Thrombocytopenia is a common problem in patients with cancer. Although chemotherapy and radiation are the major causes of thrombocytopenia in patients with cancer, other etiologies should be considered in all patients. Thrombocytopenia creates numerous problems in the care of a patient with cancer. Pharmacists must be familiar with the epidemiology, pathophysiology, risk factors, diagnostic strategies, and current treatment options for chronic ITP, to best identify and utilize practical approaches when managing patients with chronic ITP who are receiving cancer treatment.

Target audience: Specialty pharmacists
Type of activity: Application
Release date: October 30, 2020
Expiration date: November 30, 2021
Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Examine the epidemiology, pathophysiology, diagnosis, and impact of chronic immune thrombocytopenia (ITP) among patients with cancer
• Analyze the latest efficacy and safety data as well as dosing and administration of current pharmacologic treatments for chronic ITP
• Illustrate the role of the oncology pharmacist in the management of chronic ITP

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-20-315-H01-P.  The activity is available for CE credit through November 30, 2021.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Julianne O. Darling, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

• Speakers Bureaus: Merck Sharp & Dohme, AstraZeneca

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Ann Marciano; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms